https://tirzepatideprovidercomparison.comIndependent evidence, pricing and provider research on tirzepatide and GLP-1 care.en-us2026-07-26https://tirzepatideprovidercomparison.com/news/fda-503b-bulks-exclusion-proposal/https://tirzepatideprovidercomparison.com/news/fda-503b-bulks-exclusion-proposal/2026-07-24The agency found no clinical need for outsourcing facilities to compound these drugs from bulk substances. If finalised, it closes the last pathway for compounding at scale.https://tirzepatideprovidercomparison.com/news/fda-comment-period-extension-503b/https://tirzepatideprovidercomparison.com/news/fda-comment-period-extension-503b/2026-07-24FDA granted a 60-day extension after a request for more time. The window now closes days from publication, with no final determination in sight.https://tirzepatideprovidercomparison.com/news/fda-25-warning-letters-june-2026/https://tirzepatideprovidercomparison.com/news/fda-25-warning-letters-june-2026/2026-07-24The June letters continue a pattern running back to September 2025, and the target is consistent: what providers say their product is.https://tirzepatideprovidercomparison.com/news/foundayo-orforglipron-fda-approval/https://tirzepatideprovidercomparison.com/news/foundayo-orforglipron-fda-approval/2026-07-24A once-daily pill with no food or water restrictions, available from $149 a month self-pay — and the lowest mean weight reduction of any approved option.https://tirzepatideprovidercomparison.com/news/wegovy-pill-oral-semaglutide-approval/https://tirzepatideprovidercomparison.com/news/wegovy-pill-oral-semaglutide-approval/2026-07-24The first oral GLP-1 approved for weight loss, with cardiovascular risk reduction on the label and results close to the injectable.https://tirzepatideprovidercomparison.com/news/step-up-semaglutide-7-2mg/https://tirzepatideprovidercomparison.com/news/step-up-semaglutide-7-2mg/2026-07-24A threefold increase on the approved dose brings semaglutide close to tirzepatide's SURMOUNT-1 figure — if tolerability holds.https://tirzepatideprovidercomparison.com/news/medicare-glp1-bridge-launches/https://tirzepatideprovidercomparison.com/news/medicare-glp1-bridge-launches/2026-07-24For the first time Medicare covers GLP-1s for weight loss — through a demonstration programme that expires at the end of 2027 with no confirmed successor.https://tirzepatideprovidercomparison.com/news/balance-model-part-d-delayed/https://tirzepatideprovidercomparison.com/news/balance-model-part-d-delayed/2026-07-24The programme meant to succeed the Bridge has been postponed without a new date, leaving temporary access with nothing confirmed behind it.https://tirzepatideprovidercomparison.com/news/trumprx-launch-direct-pricing/https://tirzepatideprovidercomparison.com/news/trumprx-launch-direct-pricing/2026-07-24A direct-to-consumer channel advertising semaglutide tablets from $149 and tirzepatide injections from $299, against list prices above $1,000.https://tirzepatideprovidercomparison.com/news/novocare-wegovy-price-cut/https://tirzepatideprovidercomparison.com/news/novocare-wegovy-price-cut/2026-07-24A 30% reduction on the manufacturer's direct channel, and part of a broader repricing that has reshaped the affordability argument.https://tirzepatideprovidercomparison.com/news/soul-trial-oral-semaglutide-cardiovascular/https://tirzepatideprovidercomparison.com/news/soul-trial-oral-semaglutide-cardiovascular/2026-07-24A 9,647-patient outcomes trial reporting a 14% reduction in MACE and 22% in heart failure events — a hard-endpoint result in a field dominated by surrogate measures.https://tirzepatideprovidercomparison.com/news/evoke-alzheimers-null-result/https://tirzepatideprovidercomparison.com/news/evoke-alzheimers-null-result/2026-07-24A 3,808-patient, two-year programme returned a null result — and null results in this field deserve more coverage than they get.https://tirzepatideprovidercomparison.com/news/reimagine-2-cagrisema-diabetes/https://tirzepatideprovidercomparison.com/news/reimagine-2-cagrisema-diabetes/2026-07-24The furthest-advanced next-generation combination reports in type 2 diabetes, ahead of an FDA response expected during 2026.https://tirzepatideprovidercomparison.com/news/synchronize-1-visceral-liver-fat/https://tirzepatideprovidercomparison.com/news/synchronize-1-visceral-liver-fat/2026-07-24A 76-week phase 3 readout measuring where fat is lost, not only how much — which is the more clinically informative question.https://tirzepatideprovidercomparison.com/news/structure-therapeutics-oral-access-ii/https://tirzepatideprovidercomparison.com/news/structure-therapeutics-oral-access-ii/2026-07-24Structure Therapeutics reports phase 2 results with no fasting window required — a direct challenge to oral semaglutide's administration burden.https://tirzepatideprovidercomparison.com/news/fda-peptide-advisory-committee-july-2026/https://tirzepatideprovidercomparison.com/news/fda-peptide-advisory-committee-july-2026/2026-07-24Briefing documents posted in June recommended against adding any of the seven to the 503A compounding list. The committee met on 23 and 24 July.https://tirzepatideprovidercomparison.com/news/generic-tirzepatide-anda-filings/https://tirzepatideprovidercomparison.com/news/generic-tirzepatide-anda-filings/2026-07-24An ANDA filing is the start of a legal process, not an imminent launch. Anything sold as generic tirzepatide today is not one.https://tirzepatideprovidercomparison.com/news/fda-february-2026-api-restriction/https://tirzepatideprovidercomparison.com/news/fda-february-2026-api-restriction/2026-07-24The February announcement was the turn from warning letters to structural action, and the bulks proposal followed twelve weeks later.https://tirzepatideprovidercomparison.com/news/tirzepatide-shortage-timeline-litigation/https://tirzepatideprovidercomparison.com/news/tirzepatide-shortage-timeline-litigation/2026-07-24Widely reported as 'October 2024', the delisting was determined, remanded, contested and re-affirmed across five months. We had it wrong too.https://tirzepatideprovidercomparison.com/news/compounded-b12-chemical-bonding-study/https://tirzepatideprovidercomparison.com/news/compounded-b12-chemical-bonding-study/2026-07-24Additives used to differentiate compounded products from their approved counterparts are largely untested, and at least one interacts.https://tirzepatideprovidercomparison.com/news/surmount-5-published-nejm/https://tirzepatideprovidercomparison.com/news/surmount-5-published-nejm/2026-07-24751 adults, 72 weeks, maximum tolerated doses of each — the only trial that has compared these two drugs directly for weight management.https://tirzepatideprovidercomparison.com/news/summit-hfpef-results/https://tirzepatideprovidercomparison.com/news/summit-hfpef-results/2026-07-24A 731-patient phase 3 trial in a specific cardiac phenotype, with imaging substudies supporting a mechanical explanation.https://tirzepatideprovidercomparison.com/news/surmount-1-three-year-diabetes-prevention/https://tirzepatideprovidercomparison.com/news/surmount-1-three-year-diabetes-prevention/2026-07-24The longest published follow-up in this field: 1,032 participants, 176 weeks of treatment, and a hard clinical endpoint rather than a surrogate.https://tirzepatideprovidercomparison.com/news/zepbound-osa-indication/https://tirzepatideprovidercomparison.com/news/zepbound-osa-indication/2026-07-24The first GLP-1 approved for a sleep disorder, following the SURMOUNT-OSA programme — and a coverage implication for patients whose plans exclude weight management.https://tirzepatideprovidercomparison.com/news/gallup-glp1-use-obesity-decline/https://tirzepatideprovidercomparison.com/news/gallup-glp1-use-obesity-decline/2026-07-24Current use has nearly quadrupled in two years. Over the same period national obesity prevalence declined from its 2022 peak.https://tirzepatideprovidercomparison.com/news/ada-2026-bimagrumab-lean-mass/https://tirzepatideprovidercomparison.com/news/ada-2026-bimagrumab-lean-mass/2026-07-24The first strong signal that the composition of GLP-1 weight loss is pharmacologically modifiable — with a large gap still open on function.https://tirzepatideprovidercomparison.com/news/ada-2026-osteoarthritis-outcomes/https://tirzepatideprovidercomparison.com/news/ada-2026-osteoarthritis-outcomes/2026-07-24Meaningful WOMAC reduction and less analgesic use, with an asymmetry that raises a question about mechanism.https://tirzepatideprovidercomparison.com/news/wegovy-pill-three-million-prescriptions/https://tirzepatideprovidercomparison.com/news/wegovy-pill-three-million-prescriptions/2026-07-24An uptake rate suggesting the oral route addressed a real barrier rather than offering a marginal alternative.https://tirzepatideprovidercomparison.com/news/semaglutide-shortage-resolved-enforcement/https://tirzepatideprovidercomparison.com/news/semaglutide-shortage-resolved-enforcement/2026-07-24The delisting closed the pathway that had permitted compounding at scale, on a defined wind-down timetable.https://tirzepatideprovidercomparison.com/news/hims-compounded-wegovy-pill-withdrawal/https://tirzepatideprovidercomparison.com/news/hims-compounded-wegovy-pill-withdrawal/2026-07-24The episode is widely cited as the point at which FDA enforcement shifted focus from compounders to the platforms marketing them.https://tirzepatideprovidercomparison.com/news/fda-panel-votes-peptides-503a-july-2026/https://tirzepatideprovidercomparison.com/news/fda-panel-votes-peptides-503a-july-2026/2026-07-25Across 23-24 July the Pharmacy Compounding Advisory Committee recommended six of seven peptides for the 503A bulks list against unanimous staff advice, rejecting only emideltide. The votes are non-binding, each is indication-specific, and nothing is lawful yet.https://tirzepatideprovidercomparison.com/news/nad-willow-compounded-semaglutide-claims/https://tirzepatideprovidercomparison.com/news/nad-willow-compounded-semaglutide-claims/2026-07-28BBB National Programs' National Advertising Division announced on 24 July that Willow Health Services has permanently discontinued the claims. The matter had been reopened following a December 2025 decision and a referral to the FTC and state attorneys general.https://tirzepatideprovidercomparison.com/news/total-mens-primary-care-csa-settlement/https://tirzepatideprovidercomparison.com/news/total-mens-primary-care-csa-settlement/2026-07-28The US Attorney for the Western District of Texas announced that Total MD Physicians Group, trading as Total Men's Primary Care, and Dr Mason Jones agreed to pay civil penalties to resolve alleged Controlled Substances Act violations. The claims are allegations only and there has been no determination of liability.https://tirzepatideprovidercomparison.com/news/idaho-physician-sentenced-telemedicine-orders/https://tirzepatideprovidercomparison.com/news/idaho-physician-sentenced-telemedicine-orders/2026-07-28A federal judge sentenced Dr David Antonio Becerril of Coeur d'Alene, Idaho, and ordered more than $1.25 million in restitution. Prosecutors said he spent about 26 seconds on each order.https://tirzepatideprovidercomparison.com/news/cms-2027-remote-monitoring-outsourcing/https://tirzepatideprovidercomparison.com/news/cms-2027-remote-monitoring-outsourcing/2026-07-28The proposed CY2027 Physician Fee Schedule would require remote physiologic and therapeutic monitoring to be furnished by a practice's own employed clinical staff. It is not final and comments run to 14 September 2026.https://tirzepatideprovidercomparison.com/news/nexlife-names-fulfilment-pharmacies/https://tirzepatideprovidercomparison.com/news/nexlife-names-fulfilment-pharmacies/2026-07-28NexLife's plan pages name five partners and disclose both 503A and 503B pathways. It is the first provider of 29 to answer the pharmacy question, and the first to have answered all four of our disclosure questions.